Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?-Reference-Cited by-同舟云学术

Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?

Published:2021-02-15 Issue: Volume:12 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Sponaas Anne Marit,Waage Anders,Vandsemb Esten N.,Misund Kristine,Børset Magne,Sundan Anders,Slørdahl Tobias Schmidt,Standal Therese

Abstract

In this review article we discuss the role of the memory T cells in multiple myeloma (MM) and how they may influence immune responses in patients that received immunomodulating drugs and check point therapy.

Funder

Kreftforeningen

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference81 articles.

1. Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study;Mateos;Br J Haematol.,2019

2. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial;Mateos;Lancet Haematol.,2019

3. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial;Usmani;Lancet Haematol.,2019

4. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies;Guillerey;Cell Mol Life Sci.,2016

5. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment;Nakamura;Cancer Cell.,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study;Blood;2024-08-08

2. Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status;Frontiers in Immunology;2022-12-20

3. PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo;Cancer Letters;2022-10

4. Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma;Cancers;2021-04-22